Northwire Canada EditionTuesday, July 21, 2026
Sign inSubscribe
Northwire
⌕
LOD 0.280 −5.1% FVL 0.970 +6.6% BAG 0.210 +23.5% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.405 +0.0% PNTR 0.320 +8.5% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.355 +0.0% TOM 0.115 +9.5% ALS 57.05 +0.2% LIO 0.130 −7.1% GEMC 0.020 +0.0% CBA 0.070 +7.7% PUMA 0.110 +0.0% LOD 0.280 −5.1% FVL 0.970 +6.6% BAG 0.210 +23.5% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.405 +0.0% PNTR 0.320 +8.5% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.355 +0.0% TOM 0.115 +9.5% ALS 57.05 +0.2% LIO 0.130 −7.1% GEMC 0.020 +0.0% CBA 0.070 +7.7% PUMA 0.110 +0.0%
Regulatory

Quantum Biopharma granted product licence for Qlarity

By The Northwire Desk — AI Analysis Sep 18, 2025 · 17:58 QNTM · 27.75 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Health Canada has granted a Natural Health Product (NHP) license (PN 80144141) to Quantum Biopharma Ltd. for its innovative product, Qlarity™.
  • This license permits Quantum Biopharma to sell Qlarity in the Canadian market, marking a significant milestone in the company's mission to bring innovative products to market.
  • Qlarity is a natural health product designed to enhance energy, metabolism, mental alertness, and cognitive performance, with a similar product already licensed for sale in the United States under the brand name unbuzzd.

Key Details

  • Regulatory Body: Health Canada (Natural Health Products Directorate).
  • Product Name: Qlarity™.
  • License Number: PN 80144141.
  • Product Type: Natural Health Product (NHP).
  • Approved Indications/Uses:
    • Helps in energy production and metabolism.
    • Helps to maintain/support normal electrolyte balance.
    • Helps (temporarily) to enhance physical energy and motor performance.
    • Reduces fatigue.
    • Promotes endurance.
    • Promotes mental alertness.
    • Enhances cognitive performance.
  • International Context: Quantum Biopharma previously licensed a similar product as a dietary supplement for sale in the United States under the brand name "unbuzzd."
  • Strategic Impact: The approval allows the company to leverage the product's potential to improve consumer well-being and expand its market presence in Canada.

Notable Quotes

  • Zeeshan Saeed, CEO: "This is a milestone in Quantum Biopharma's mission to bring innovative products to the market... We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being."
  • Professor Lakshmi P. Kotra, Board Director: "I am delighted that the Natural Health Products Directorate at Health Canada has provided a product licence for Qlarity... I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other